Hims & Hers Health surged 6.31% in pre-market trading on Thursday, marking a significant upward movement for the telehealth company.

The sharp increase appears to be driven by the company's announcement that providers delivering ongoing care to Hims & Hers customers can now prescribe FDA-approved GLP-1 treatments, with medications fulfilled by independent pharmacies. This expansion into the GLP-1 treatment market represents a strategic move to capitalize on the growing demand for these therapies, which are widely used for weight management and related conditions.

The ability to offer FDA-approved GLP-1 medications through its platform could significantly expand Hims & Hers' service offerings and revenue potential in the competitive telehealth sector.